Our previous study reported multi-drug resistance (MDR) reversing properties of synthetic stemofoline derivatives (STFD), OH-A1, NH-B6 and NH-D6 on P-glycoprotein (P-gp) overexpressing leukaemic cells (K562/Adr); however, the mechanism was unclear. In this study, we further investigated whether the STFD reverse MDR through either the inhibition of P-gp function or expression in K562/Adr cells, or both. The Pgp functional studies showed that the STFD increased the accumulation of calcein-AM, rhodamine 123 and [14C]-doxorubicin in K562/Adr cells, while the effects have not been seen in their parental sensitive cancer cell line (K562). Further, the STFD did not alter the P-gp expression as determined by Western blotting. This study concludes that the STFD reverse MDR via the inhibition of P-gp function. The efficacy of the STFD to inhibit P-gp function followed the order: NH-B6 > OH-A1 > NH-D6. These compounds could be introduced as candidate molecules for treating cancers exhibiting P-gp-mediated MDR.
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Abstract: Our previous study reported multidrug resistance (MDR) reversing properties of synthetic stemofoline derivatives (STFD), OH-A1, NH-B6 and NH-D6 on P-glycoprotein (P-gp) over-expressing leukemic cells (K562/Adr), however, the mechanism was unclear. In this study, we further investigated whether the STFD reverse MDR through either the inhibition of P-gp function or expression in K562/Adr cells, or both. The P-gp functional studies showed that the STFD increased the accumulation of calcein-AM, rhodamine123 and [
C]-doxorubicin in
K562/Adr cells while the effects have not been seen in their parental sensitive cancer cell line (K562). The STFD did not alter the P-gp expression as determined by Western blotting. This study concludes that the STFD reverse MDR via inhibition of P-gp function. The efficacy of the STFD to inhibit P-gp function followed the order: NH-B6 > OH-A1 > NH-D6. These compounds could be introduced as candidate molecules for treating cancers exhibiting P-gpmediated MDR.
Chemotherapy is one of the standard methods in the treatment of leukaemia, which is capable of inducing cancer cell death. However, many leukaemia patients experience recurrence and ultimately death because of treatment failure. Drug resistance is one cause of the failure that can be due to cell-intrinsic mechanisms or acquired de novo during the course of the treatment [1] . The development of resistance to chemotherapeutic agents is related to multiple mechanisms such as alterations in drug transport, changes in cellular proteins involved in detoxification, altered drug target, changes in DNA repair mechanisms and activation of key signalling pathways [2] .
P-glycoprotein (P-gp), which is encoded by the MDR1 gene, is proven to be responsible for resistance to a variety of structurally and functionally unrelated anti-tumour drugs, including vinblastine, vincristine, doxorubicin and paclitaxel. This transporter uses the energy that is released upon hydrolysis of ATP to drive the transport of various molecules across the cell membrane. The efflux of anti-cancer drugs by this pump causes a decrease in intracellular drug accumulation leading to cancer cell survival and treatment failure [2] .
Adjuvant chemotherapy against MDR cancer using agents from natural sources has therefore been of interest. For example, curcumin from Curcuma longa [3, 4] , kuguacin J from
Momordica charantia [5] , and chelidonine from Chelidonium majus [6] have been reported as effective P-gp inhibitors in various types of human MDR cancer cells. The advantage of these dietary herbs is that they often exhibit little or virtually no side effects and do not add to a patient's medication burden.
In our previous study, twelve STFD derivatives were synthesized, and their cytotoxicity and effect on doxorubicin (DOX) and paclitaxel (PTX) sensitivity in drug-resistant (K562/Adr) and drug-sensitive (K562) cells was determined. [7] . We found that three active STFD including OH-A1, NH-B6 and NH-D6 could re-sensitize the human MDR leukaemic cell to the chemotherapeutic drugs [7] . However, the mode of action of the STFD on P-gp inhibition 4 was unclear. In this study, we therefore aimed to investigate whether the STFD can reverse MDR through inhibition of P-gp function or expression in human MDR leukaemic cells (K562/Adr), or both. C]-DOX in the treated cells was detected using a liquid scintillation betacounter as previously described [9] . In each experiment, determinations were carried out in triplicate. and HRP-conjugated mouse anti-mouse IgG (1:10,000) [12, 13] .
Materials and Methods
Drugs and reagents
Western blot analysis
Cytotoxicity of STFD on human fibroblasts and peripheral blood mononuclear cells (PBMCs) by MTT assay
Fibroblasts were plated at 3×10 
Results
STFD enhanced chemotherapeutic drugs sensitivity in MDR leukaemic cells
DOX is a cell cycle non-specific agent and a drug of choice for treatment of leukaemic patients, which produces ROS and inhibits topoisomerase II leading to chromatin aggregation [14] , while PTX is a highly specific P-gp substrate anti-cancer drug that inhibits microtubule depolarization within the cancer cells leading to G2/M phase arrest [15, 16] . Our previous studies found that co-treatment of STFD could increase cytotoxicity of DOX and PTX in the MDR leukaemic cells using the MTT assay [7] . In this study, cell cycle determination in K562/Adr cells was performed to confirm that the cytotoxicity or growth inhibition was due to the action of the anti-cancer drugs. DOX single treatment caused cell accumulation at the G2/M phase while the accumulation was shifted to sub-G1 (cell death) and S populations when the cells were co-treated with STFD, especially NH-B6 ( fig. 2A-2D ). Combination treatment of PTX and STFD in K562/Adr cells significantly enhanced G2/M arrest whereas the cell cycle profile was not altered in the PTX single treatment when compared to the control ( fig. 2D-2G ). These results have suggested that the cytotoxicity and growth inhibition were due to the effect of the anti-cancer drugs which were accumulated in the MDR cells by the STFD. STFD alone did not change the cell cycle profile when compared to the vehicle control.
STDF increased the accumulation of P-gp fluorescent substrates
C-AM and Rho123 have been known to be substrates for P-gp that could be used to determine whether the STFD modulate intracellular drug levels by inhibiting P-gp function [9, 10] . The accumulation of C-AM and Rho123 was determined using flow cytometry. 
STFD increase radioactive-labelled chemotherapeutic drug, [ 14 C]-DOX accumulation
Previous experiments showed that the ability of the STFD to increase the accumulation of Pgp fluorescent substrates in K562/Adr cells which further suggested that the STFD could inhibit P-gp function. In this current study, DOX, labelled with [ 
STFD did not alter P-gp expression
Over-expression of the P-gp has been well established as the cause of the MDR phenotypein vitro on selected drug-resistant cells [2] . K562/Adr cells have been shown to express P-gp at a high level on their plasma membrane. The MDR reversal by the chemosensitizers might be due to their inhibition of the P-gp expression. STFD were assessed of their ability to modulate the P-gp expression via Western blot analysis. It was found that P-gp expression did not differ between the control and the treatment groups ( fig. 5 ). These results suggested that the MDR reversing property of the STFD was not involved with the down-regulation of the P-gp expression.
Effects of STFD on the cytotoxicity of human fibroblasts and PBMCs
Previous studies have shown that 0-40 µM of the STFD were not toxic to K562 and K562/Adr cells using the MTT assay [7] . In this current study, the cytotoxicity of the STFD on human normal cells was investigated. We found that the survival of human fibroblasts (normal human skin tissue primary cells) and PBMCs (normal human white blood cells) was more than 90% after the treatment ( fig. 6a-b) .
Discussion
Several studies have described an increase in the P-gp expression after initial chemotherapy treatment that has repeatedly been linked to poor outcomes in some forms of leukaemia [17, 18] . Chemosensitizers or MDR modulators are agents that can affect the drug accumulation detected in the MDR cells, but there is no potentiation of drug cytotoxicity in sensitive cells.
The magnitude of chemosensitizers' effects can be determined by comparing the IC 50 values of a cytotoxic drug in the absence and presence of a relatively non-toxic and fixed concentration of a chemosensitizer [18] . VER and CSA have been reported as MDR modulators [4, 7, 9, 13, 19] but they have limited clinical use due to their side effects, such as hypertension and immunosuppression [20] . Tyrosine Kinase Inhibitors (TKI) are a class of commercial, adjuvant agents used against MDR cancers, for example imatinib, [21] which has shown adverse effects in the thyroid gland and the heart and also can lead to TKI resistance cancers [22, 23] . Our recent studies aimed to discover and develop high potential MDR modulators that have no toxicity or adverse drug effects.
In our previous study, three stemona alkaloids, stemocurtisine, oxystemokerrine and stemofoline (STF), were isolated from Stemona burkillii and investigated for their biological activities. We found that STF exhibited the most potent MDR reversal effect in human MDR cervical carcinoma cells [19] . While these alkaloids all have relatively complex multi-cyclic ring structures, ring A in the former two alkaloids is six-membered (piperidine ring) while the one in STF is a five-membered ring (pyrrolidine ring) [8, 24] . Furthermore, STF has a more complex caged structure ( fig. 1 ) than that of stemocurtisine and oxystemokerrine. These differences in the ring structure may contribute to the deference in their abilities to reverse MDR. Structural modification of STF might enhance its biological activity leading to more effective MDR reversing agents for cancer therapy. Subsequently, we then studied the effect of synthetic STFD on the P-gp mediated multidrug resistance in human MDR cancer cells.
expression [5, 25, 26] . However, other natural products, such as curcumin, α-asarone and β-asarone have been reported as effective chemosensitizers able to down-regulate both MDR1
gene expression and the P-gp function in various types of human MDR cancer cells [3, 4, 27] .
The P-gp contains six putative transmembrane helices and one nucleotide binding/utilization domain (NBD), also called the ATP site [28] . In order to inhibit the drug export function of the P-gp, aclass of compounds known as modulators,can block its function via direct interaction with the P-gp and appear to compete with drugs for the substrate-binding site(s) on the protein. Our previous study reported that STF isolated from Stemona burkillii inhibited the P-gp function by acting on the substrate-binding site determined by photoaffinity labelling assay [9] . For additional studies on drug P-gp binding, P-gp ATPase activity was stimulated by STF in a concentration-dependent manner. Therefore, the action of the STFD may interact directly with the P-gp and inhibit its activity in a similar manner to that of STF.
The multi-cyclic ring, the pyrrolidine ring contained in STF and STFD structure, may incorporate into ligand-binding site that could inhibit the P-gp function. In another study, a cell-based screening technique was used to screen the NCI Structural Diversity Set for smallmolecule compounds capable of reversing MDR [29] . One of the most potent small molecules in this screening was tetrandrine, a bis-benzylisoquinoline alkaloid compound isolated from the root of Stephania tetrandra. Tetrandrine has been reported to reverse drug resistance via simulating ATPase activity. However, it did not alter the protein expression level of the P-gp. The MDR modulating effect of tetrandrine was similar to our finding using natural stemofoline isolated from Stemona burkillii in a previous report [9] . We have 
